

# Supporting Information

## A Modular, One-pot, Sequential Aziridine Ring Opening–S<sub>N</sub>Ar Strategy

### to 7-, 10- and 11-membered Benzofused Sultams


Joanna K. Loh, Naeem Asad, Thiwanka B. Samarakoon, and Paul. R. Hanson\*

*Department of Chemistry, University of Kansas, 1251 Wescoe Hall Drive, Lawrence, KS 66045-7582 and the Center for Chemical Methodologies and Library Development at the University of Kansas (KU-CMLD), 2034 Becker Drive, Shankel Structural Biology Center, Lawrence, Kansas 66047.*

phanson@ku.edu



### Table of Contents

Table of Optimization of Reaction Conditions	SI-2
<sup>19</sup> F NMR Spectra for Compounds A, B and C	SI-3
<sup>1</sup> H, <sup>13</sup> C NMR Spectra and Crystallographic Data for All Relevant Compounds	SI-4–SI-55

**Table 1.** Optimization of reaction conditions



entry <sup>h</sup>	R <sup>1</sup> , R <sup>2</sup>	conc (i to ii M)	time (i, ii mins)	base	yield (%) <sup>a</sup>
1	F, <sup>i</sup> Bu	1.0 to 0.3	20, 60	Cs <sub>2</sub> CO <sub>3</sub>	23 <sup>b</sup>
2	F, <sup>i</sup> Bu	0.8 to 0.3	20, 60	Cs <sub>2</sub> CO <sub>3</sub>	43 <sup>b</sup>
3	F, <sup>i</sup> Bu	0.5 to 0.3	20, 60	Cs <sub>2</sub> CO <sub>3</sub>	40 <sup>b</sup>
4	F, <sup>i</sup> Bu	1.0 to 0.3	5 d <sup>c</sup> , 60	Cs <sub>2</sub> CO <sub>3</sub>	23
5	F, <sup>i</sup> Pr	0.8 to 0.3	20, 60	CsF	3 <sup>d</sup>
6	F, <sup>i</sup> Pr	0.8 to 0.3	20, 60	K <sub>2</sub> CO <sub>3</sub>	18 <sup>e</sup>
7	F, <sup>i</sup> Pr	0.8 to 0.3	20, 60	K <sub>3</sub> PO <sub>4</sub>	11 <sup>d</sup>
8	F, <sup>i</sup> Pr	0.8 to 0.3	20, 60	DBU	4 <sup>f</sup>
9	F, <sup>i</sup> Pr	0.8 to 0.3	20, 60	NaH	11 <sup>g</sup>

<sup>a</sup>Final isolated yield over 2 reactions after flash chromatography. <sup>b</sup>**Aziridine-opening:** **1** (1.0 equiv) and **2** (1.05–1.3 equiv) in DMF at 130 °C. **S<sub>N</sub>Ar:** Cs<sub>2</sub>CO<sub>3</sub> (2.5 equiv) in DMF at 150 °C. <sup>c</sup>Aziridine-opening: reaction stirred at rt for 5 days. <sup>d</sup>CsF or K<sub>3</sub>PO<sub>4</sub> (2.0 equiv). <sup>e</sup>K<sub>2</sub>CO<sub>3</sub> (3.0 equiv). <sup>f</sup>DBU (0.3 equiv). <sup>g</sup>NaH (2.2 equiv). <sup>h</sup>Reactions were monitored by TLC.





**Figure 1.** <sup>19</sup>F NMR studies: comparison between sulfonamide **A**, ring opened **B** and product **C**.



**(S)-1-((4-bromo-2-fluorophenyl)sulfonyl)-2-isopropylaziridine (4b)**





**(S)-1-((2,4-difluorophenyl)sulfonyl)-2-isopropylaziridine (4d)**





**(S)-10-bromo-3-isobutyl-5-methyl-2,3,4,5,6,7-hexahydrobenzo[*b*][1,4,5,8]oxathiadiazecine 1,1-dioxide (6a)**



**Figure 1.** X-ray crystal structure of sultam **6a** where the thermal ellipsoids are set at a 50% probability level.





**(S)-10-bromo-3-isopropyl-5-methyl-2,3,4,5,6,7-hexahydrobenzo[*b*][1,4,5,8]oxathiadiazecine-1,1-dioxide (6b)**








**(S)-10-fluoro-3-isobutyl-5-methyl-2,3,4,5,6,7-hexahydrobenzo[*b*][1,4,5,8]oxathiadiazecine 1,1-dioxide (6c)**




**(S)-10-fluoro-3-isopropyl-5-methyl-2,3,4,5,6,7-hexahydrobenzo[*b*][1,4,5,8]oxathiadiazecine-1,1-dioxide (6d)**




**(S)-11-chloro-3-isopropyl-5-methyl-2,3,4,5,6,7-hexahydrobenzo[*b*][1,4,5,8]oxathiadiazecine 1,1-dioxide (6e)**





**(S)-3-((S)-*sec*-butyl)-11-chloro-5-methyl-2,3,4,5,6,7-hexahydrobenzo[*b*][1,4,5,8]oxathiadiazecine 1,1-dioxide (6f)**





**12-fluoro-5-methyl-4,5,6,7-tetrahydro-2H-spiro[benzo[*b*][1,4,5,8]oxathiadiazecine-3,1'-cyclohexane] 1,1-dioxide (6g)**




**(6*S*,14*aR*)-11-bromo-6-isobutyl-1,2,3,5,6,7,14,14a-octahydrobenzo[*b*]pyrrolo[1,2*h*][1,4,5,8]oxathiazine 8,8-dioxide (6h)**



**(6*S*,14*aR*)-11-fluoro-6-isopropyl-1,2,3,5,6,7,14,14*a*-octahydrobenzo[*b*]pyrrolo[1,2*h*][1,4,5,8]oxathiazine 8,8-dioxide (6i)**





**(6*S*,14*aR*)-6-((*S*)-*sec*-butyl)-10-chloro-1,2,3,5,6,7,14,14*a*-octahydrobenzo[*b*]pyrrolo[1,2-*h*][1,4,5,8]oxathiazine 8,8-dioxide (6j)**








**(6*S*,14*aR*)-6-((*S*)-*sec*-butyl)-9-fluoro-1,2,3,5,6,7,14,14*a*-octahydrobenzo[*b*]pyrrolo[1,2-*h*][1,4,5,8]oxathiazine 8,8-dioxide (6k)**





**(6*S*,14*aS*)-11-fluoro-6-isopropyl-1,2,3,5,6,7,14,14*a*-octahydrobenzo[*b*]pyrrolo[1,2-*h*][1,4,5,8]oxathiazine 8,8-dioxide (6l)**




**(R)-9-fluoro-2,3,5,7,14,14a-hexahydro-1H-spiro[benzo[*b*]pyrrolo[1,2-*h*][1,4,5,8]oxathiadiazecine-6,1'-cyclohexane] 8,8-dioxide (6m)**




**(7S)-2-bromo-7-isopropyl-7,8,10,11,12,13,13a,14-octahydro-6H-benzo[b]pyrido[1,2-h][1,4,5,8]oxathiazine 5,5-dioxide (6n)**





**(7S)-2-bromo-7-isobutyl-6,7,8,10,11,12,13,13a,14,15-decahydrobenzo[*b*]pyrido[1,2-*h*][1,4,5,8]oxathiazacycloundecine 5,5-dioxide (60)**




**(7*S*,13*aS*)-2-bromo-7-isopropyl-6,7,8,10,11,12,13,13*a*,14,15-decahydrobenzo[*b*]pyrido[1,2-*h*][1,4,5,8]oxa-thiadiazacycloundecine 5,5-dioxide (6p)**



**Figure 2.** X-ray crystal structure of sultam **6p** where the thermal ellipsoids are set at a 50% probability level.





**3*S*,6*S*,7*R*)-10-fluoro-3-isopropyl-5,6-dimethyl-7-phenyl-2,3,4,5,6,7-hexahydrobenzo[*b*][1,4,5,8]oxathiazine 1,1-dioxide (8a)**








**(3*S*,6*R*,7*R*)-10-fluoro-3-isopropyl-5,6-dimethyl-7-phenyl-2,3,4,5,6,7-hexahydrobenzo[*b*][1,4,5,8]oxathiazine 1,1-dioxide (8b)**




**Figure 3.** X-ray crystal structure of sultam **8b** where the thermal ellipsoids are set at a 50% probability level.







**(3*S*,6*S*,7*S*)-10-bromo-3-isopropyl-5,6-dimethyl-7-phenyl-2,3,4,5,6,7-hexahydrobenzo[*b*][1,4,5,8]oxathiazine 1,1-dioxide (8c)**




**(3*S*,6*S*,7*S*)-10-fluoro-3-isobutyl-5,6-dimethyl-7-phenyl-2,3,4,5,6,7-hexahydrobenzo[*b*][1,4,5,8]oxathiazine 1,1-dioxide (8d)**





**(3*S*,6*S*)-10-fluoro-3,6-diisobutyl-5-methyl-2,3,4,5,6,7-hexahydrobenzo[*b*][1,4,5,8]oxathiadiazecine-1,1-dioxide (8e)**



**(S)-10-fluoro-3-isobutyl-5-methyl-3,4,5,7-tetrahydro-2H-spiro[benzo[*b*][1,4,5,8]oxathiadiazecine-6,1'-cyclohexane] 1,1-dioxide (8f)**




**(S)-3-isopropyl-7-methyl-5-propyl-2,3,4,5-tetrahydrobenzo[*f*][1,2,5]thiadiazepine 1,1-dioxide (10a)**









**(S)-7-bromo-5-butyl-3-isobutyl-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepine 1,1-dioxide (10b)**




**(S)-5-benzyl-7-bromo-3-isobutyl-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepine 1,1-dioxide (10c)**




**(S)-7-bromo-3-isobutyl-5-(4-isopropylbenzyl)-2,3,4,5-tetrahydrobenzo[*f*][1,2,5]thiadiazepine 1,1-dioxide (10d)**




**(S)-9-fluoro-3-isopropyl-5-(4-(trifluoromethyl)benzyl)-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepine 1,1-dioxide (10e)**



**(S)-3-isopropyl-7-methyl-5-(oxetan-3-yl)-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepine 1,1-dioxide (10f)**




**(S)-9-fluoro-3-isopropyl-5-(3-methoxypropyl)-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepine 1,1-dioxide (10g)**




**(S)-3-((S)-sec-butyl)-8-chloro-5-(3-methoxypropyl)-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepine 1,1-dioxide (10h)**

**1,1-**




**9-fluoro-5-(3-methoxypropyl)-4,5-dihydro-2H-spiro[benzo[f][1,2,5]thiadiazepine-3,1'-cyclohexane] 1,1-dioxide (10i)**







7-bromo-5-(2-hydroxyethyl)-4,5-dihydro-2H-spiro[benzo[f][1,2,5]thiadiazepine-3,1'-cyclohexane] 1,1-dioxide (10j)


1,1-




**(S)-7-bromo-5-(2-hydroxyethyl)-3-isopropyl-2,3,4,5-tetrahydrobenzo[*f*][1,2,5]thiadiazepine 1,1-dioxide (10k)**





**(S)-7-bromo-5-(2-hydroxyethyl)-3-isobutyl-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepine 1,1-dioxide (101)**



**(S)-7-bromo-5-((R)-1-hydroxypropan-2-yl)-3-isobutyl-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepine 1,1-dioxide (10m)**




**Figure 4.** X-ray crystal structure of sultam **10m** where the thermal ellipsoids are set at a 50% probability level.







**(S)-7-bromo-5-(1-(hydroxymethyl)cyclohexyl)-3-isopropyl-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepine 1,1-dioxide (10n)**





**(S)-7-bromo-5-((S)-1-hydroxy-4-methylpentan-2-yl)-3-isobutyl-2,3,4,5 tetrahydrobenzo[f][1,2,5]thiadiazepine 1,1-dioxide (10o)**









**(S)-7-bromo-5-((R)-4-hydroxy-3-methylbutyl)-3-isobutyl-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepine 1,1-dioxide (10p)**




**(3S)-7-bromo-3-isobutyl-3,4-dihydro-2,5-ethanobenzo[*f*][1,2,5]thiadiazepine 1,1-dioxide (11a)**





**(4*R*,11*S*)-7-bromo-11-isobutyl-4-methyl-3,4-dihydro-2,5-ethanobenzo[*f*][1,2,5]thiadiazepine 1,1-dioxide (11b)**




**7-bromo-4H-spiro[2,5-ethanobenzo[f][1,2,5]thiadiazepine-3,1'-cyclohexane] 1,1-dioxide (11c)**



**Figure 5.** X-ray crystal structure of sultam **11c** where the thermal ellipsoids are set at a 50% probability level.



**(3*S*,7*R*)-7-((benzyloxy)methyl)-10-fluoro-5-((*R*)-1-hydroxypropan-2-yl)-3-isobutyl-2,3,4,5,6,7hexahydrobenzo[*b*][1,4,5,8]oxathiadiazecine 1,1-dioxide (18)**



**(3*S*,7*S*)-7-((benzyloxy)methyl)-10-fluoro-5-((*R*)-1-hydroxypropan-2-yl)-3-isobutyl-2,3,4,5,6,7hexahydrobenzo[*b*][1,4,5,8]oxathiadiazecine 1,1-dioxide (19)**

